
Monopar Therapeutics (MNPR) P/E Ratio
P/E Ratio as of Jun 13, 2025: -8.41
Average-8.70
Median-8.77
Minimum-9.54
Maximum-7.53
-8.41
Past Month+1.51 (15.22%)
The P/E ratio for Monopar Therapeutics (MNPR) is -8.41 as of Jun 13, 2025. This represents a increase of 2.31% compared to its 12-month average P/E ratio of -8.22. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Monopar Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Monopar Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Monopar Therapeutics to industry peers.
Monopar Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Monopar Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Monopar Therapeutics to industry peers.
Monopar Therapeutics (MNPR) P/E Ratio Insights
See Monopar Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Monopar Therapeutics (MNPR)
Order type
Buy in
Order amount
Est. shares
0 shares
Monopar Therapeutics (MNPR) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $30.01 | -7.53 |
May 1, 2025 | $43.15 | -10.47 |
Apr 1, 2025 | $33.43 | -8.11 |
Mar 3, 2025 | $30.93 | -15.60 |
Feb 3, 2025 | $43.55 | -21.97 |
Jan 2, 2025 | $22.22 | -11.21 |
Monopar Therapeutics (MNPR) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -8.41 | -24.23% |
2024 | -11.10 | +2,212.50% |
2023 | -0.48 | -83.51% |
2022 | -2.91 | -33.86% |
2021 | -4.40 | -58.88% |
2020 | -10.70 | — |
FAQs About Monopar Therapeutics (MNPR) P/E ratio
The latest P/E ratio of Monopar Therapeutics (MNPR) is -8.41, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Monopar Therapeutics’s last 12-month average P/E ratio is -8.22, compared to its current P/E ratio of -8.41. This reflects a increase of 2.31%.
Monopar Therapeutics’s current P/E ratio of -8.41 is higher than its last 12-month average P/E of -8.22. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Monopar Therapeutics’s average P/E ratio over the last 3 years is -3.91. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Monopar Therapeutics’s average P/E ratio over the last 5 years is -5.82. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.